Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Disease Risk Clear all
Terminated Phase 2 Interventional Results available

MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

NCT03218163
View directory record Official record
Conditions
Multiple Myeloma
Interventions
MEDI-551 Maintenance
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 10, 2026, 1:19 PM EDT
Completed No phase listed Observational

Stroke Incidence and Risk Factors in a Tri-ethnic Region

NCT03266952
View directory record Official record
Conditions
Diabetes, Diet, Epidemiology, Stroke, Myocardial Infarction
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
40 Years and older
Enrollment
3,497 participants
Timeline
1993 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 10, 2026, 1:19 PM EDT
Terminated Phase 1 Interventional

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT00725062
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
Biological · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 10, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients

NCT02412982
View directory record Official record
Conditions
Traumatic Injury, Venous Thromboembolism
Interventions
Enoxaparin 40 mg q12h, Enoxaparin 30 mg q8h
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 10, 2026, 1:19 PM EDT
Recruiting Phase 4 Interventional

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

NCT06632379
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Atorvastatin 10 mg, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 10, 2026, 1:19 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

NCT00039676
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin Disease, NonHodgkin Lymphoma, Mixed Lymphoproliferative Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Months and older
Enrollment
1,836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 1:19 PM EDT
Recruiting Phase 2 Interventional

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
Interventions
HSCT with TBI Regimen, HSCT with Non-TBI Regimen
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 10, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

World Trade Center Adolescent Health Study

NCT02068183
View directory record Official record
Conditions
Asthma, Hypertension, Cardiovascular Risk Factor, Insulin Resistance, Stress Disorders, Post-Traumatic, Exposure to Toxic Dust
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 20 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 10, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT00064311
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ravuconazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 10, 2026, 1:19 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

NCT07448038
View directory record Official record
Conditions
Atherosclerosis
Interventions
Selnoflast, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of ZIO-101 in Hematologic Cancers

NCT00592046
View directory record Official record
Conditions
Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma, Lymphoma, Poor-risk Myelodysplasia (MDS)
Interventions
ZIO-101 (Darinaparsin)
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 10, 2026, 1:19 PM EDT
Active, not recruiting Not applicable Interventional

CTSN Embolic Protection Trial

NCT06027788
View directory record Official record
Conditions
Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Interventions
CardioGard Embolic Protection Cannula, Standard Aortic Cannula
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years and older
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
North Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Personalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes

NCT01134458
View directory record Official record
Conditions
Cardiovascular Disease, Peripheral Artery Disease, Ischemic Stroke, Diabetes
Interventions
Web-Based Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 10, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional

Combination Study for High Risk Multiple Myeloma Patients

NCT03104270
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Encinitas, California • Fountain Valley, California • Monterey, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 10, 2026, 1:19 PM EDT
Active, not recruiting Phase 3 Interventional

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756
View directory record Official record
Conditions
Arteriosclerosis, Hypercholesterolaemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
14,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
132
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 10, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease

NCT02646488
View directory record Official record
Conditions
Cardiovascular Disease, High Blood Pressure
Interventions
Million Hearts ABCS 6 Months, Million Hearts ABCS 9 Months, Million Hearts ABCS 12 Months, Million Hearts ABCS 15 Months, Standard Care Regimen 9 Months, Standard Care Regimen 12 Months, Standard Care Regimen 15 Months, Standard Care Regimen 18 Months, Standard Care Regimen 21 Months, Standard Care Regimen 24 Months, Standard Care Regimen 27 Months, Follow Up Post Intervention 21 Months, Follow Up Post Intervention 24 Months, Follow Up Post Intervention 27 Months, Follow Up Post Intervention 30 Months, Follow Up Post Intervention 33 Months
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 10, 2026, 1:19 PM EDT
Completed No phase listed Observational

Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm

NCT01595802
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Nautilus NeuroWave, Transcranial Doppler (TCD)
Device
Lead sponsor
Jan Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 10, 2026, 1:19 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

NCT04270409
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 10, 2026, 1:19 PM EDT
Recruiting Not applicable Interventional

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

NCT07296744
View directory record Official record
Conditions
Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Interventions
The Supira System, Impella
Device
Lead sponsor
Supira Medical
Industry
Eligibility
18 Years to 90 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Loma Linda, California • Sacramento, California • Thousand Oaks, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 10, 2026, 1:19 PM EDT
Withdrawn No phase listed Observational

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

NCT01809730
View directory record Official record
Conditions
Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 10, 2026, 1:19 PM EDT
Not listed No phase listed Observational

Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) Population

NCT00431405
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease, Coronary Disease
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2007 · Synced Oct 10, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Giving a Low Carbohydrate Diet to Overcome Hypertension

NCT04230928
View directory record Official record
Conditions
Hypertension, African Americans, Diet, Carbohydrate-Restricted, Risk Reduction Behavior
Interventions
Very low carbohydrate diet, Standard DPP-GLB diet, Standard DPP-GLB program modules
Other · Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 74 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 10, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Coordinating Pragmatic Primary Care Population Management for Obesity

NCT03998046
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factor
Interventions
Outreach Support for Weight Loss Goal Setting and Self-Weighing, Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions, Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 10, 2026, 1:19 PM EDT
Completed Phase 4 Interventional

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

NCT00095290
View directory record Official record
Conditions
Albuminuria
Interventions
Ramipril + Irbesartan, Ramipril + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Tustin, California • Miami, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 10, 2026, 1:19 PM EDT